Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)

Screen Shot 2019-10-22 at 11.25.04

This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage